ArticleCureus2025
Comparative Analysis of Sociodemographic, Clinical Features, Laboratory Findings, and Treatment Protocols in Generalized and Localized Cutaneous Lichen Planus.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy of Dupilumab in a Young Woman with Refractory Cutaneous Lichen Planus: A Case-Based Review.Diseases (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLichen planus (LP) is a chronic, inflammatory, and mucocutaneous disease that can present in various clinical forms, affecting the skin, mucosa, and appendages of the skin. A more extensive form of cutaneous LP, known as generalized cutaneous LP (GCLP), involves a significant portion of the body surface area. Because of the accompanying intense pruritus and difficulties with its treatment, the diagnosis and treatment of GCLP are gaining importance. In this study, we aimed to compare the characteristics of cutaneous LP with localized involvement and those of GCLP.
methodsWe retrospectively analyzed patients' sociodemographic characteristics (age, gender), clinical features (localization and duration of lesions), laboratory findings, treatments received, and relapse rates following treatment using electronic medical records obtained from our university's digital registry system.
resultsAmong the patients with cutaneous LP, 24.7% (n=46) had localized cutaneous LP (LCLP), and 22.5% (n=42) had GCLP. Involvement of the trunk and flexural regions was higher among the patients with GCLP than LCLP (p<0.001 and p=0.012, respectively). Hypertriglyceridemia and hepatitis B core antibody positivity were also observed more frequently in the patients with generalized than LCLP (p=0.005 and p=0.016, respectively). Narrowband ultraviolet B and acitretin were more effective in treating patients with GCLP (p<0.001 and p=0.001, respectively). When the relapse rates in both LP groups were compared, relapses were more frequent in the patients with GCLP (p=0.022). Conclusions: The lesion localization, treatment needs, and relapse rates of patients with GCLP differ from those of patients with LCLP. This article was previously presented as an e-poster at the 32nd National Turkish Dermatology Congress on November 24, 2024.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.